Abstract Poster Wall
2025 Kidney Cancer Research Summit
Abstract 22
Final Results of the Phase 3 COSMIC-313 Study Comparing First-Line Cabozantinib Plus Nivolumab and Ipilimumab With Nivolumab Plus Ipilimumab in Patients With Advanced Renal Cell Carcinoma
Laurence Albiges
Abstract 23
Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) -MRD GATE RCC
Arpita Desai MD
Abstract 24
TGFβ alters CD8+ T cell phenotype and drives resistance to immune checkpoint inhibitors (ICI) in renal cell carcinoma (RCC)
Rishabh Rout
Abstract 25
Impact of HIF2α inhibition on T cell function in clear cell renal cell carcinoma
Katrine Madsen
Abstract 26
Subgroup Analysis of the Efficacy and Safety of Cabozantinib ± Atezolizumab in Patients From CONTACT-03 Who Received First-Line Treatment With Immuno-Oncology–Based Combinations
Bradley A McGregor
Abstract 27
Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinoma
Benjamin D. Mercier, BS
Abstract 29
An artificial intelligence model to predict somatic mutations from histopathology in metastatic renal cell carcinoma
Regina Barragan-Carrillo
Abstract 31
Lymphocyte Heat Shock Signature Predicts Response to Immune Checkpoint Blockade in Renal Cell Carcinoma
Ethan Burns
Abstract 32
Interplay of Tumor-Intrinsic and Microenvironmental Gene Expression Predicts Immune Checkpoint Blockade Response in Metastatic Renal Cell Carcinoma
Nicholas J Salgia
Abstract 33
Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma
Prathyusha Konda
Abstract 35
FGD1 Splice Variant as a Novel Biomarker for Inferior Clinical Outcomes and Development of Brain and Bone Metastasis in Clear Cell Renal Cell Carcinoma
Alex C. Soupir
Abstract 36
International Neoadjuvant Kidney Cancer Consortium guidelines on assessing pathological response after neoadjuvant therapy in kidney cancer
James O Jones
Abstract 37
Integrative multi-omic characterization of the immune landscape in renal cell carcinoma
Jennifer Pfeil
Abstract 38
Presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma
Lena Wirth
Abstract 39
Intra-tumoral Viral Transcriptomic Signatures Stratify Immune Phenotypes and Clinical Outcomes in Renal Cell Carcinoma (RCC)
Mustafa Saleh
Abstract 40
Investigating the determinants of immunotherapy response in the primary tumor of clear renal cell carcinoma (RCC)
Cerise Tang
Abstract 41
Single-cell dissection of immunosuppressive myeloid subclusters driving resistance to immune checkpoint therapy in renal cell carcinoma (RCC)
Soki Kashima
Abstract 42
The Impact of Belzutifan on Tumor Reduction Procedures and Healthcare Resource Utilization in Von Hippel–Lindau (VHL) Disease
Rimas V. Lukas
Abstract 43
AURKA Connects NSD1 and SETD2 in an Epigenetic Axis Governing Mitotic Fidelity in ccRCC
Ruhee Dere
Abstract 44
Overview of Tivozanib (Tivo) Safety in Patients with Metastatic Renal Cell Carcinoma (mRCC)
Pedro C. Barata
Abstract 45
Tumor Matrix Directed IL-12/A3 Fusion Cytokine Secreted by CD70-CAR NK Cells Markedly Enhances Anti-RCC Responses with Limited Systemic Exposure
Fuguo Liu
Abstract 46
Integrated Efficacy and Safety Exposure Response (ER) Analysis of Tivozanib (Tivo) for the Treatment of Renal Cell Carcinoma (RCC)
Bradley A McGregor
Abstract 48
Correlates of Immunotherapy Response in Metastatic Clear Cell Renal Cell Carcinoma from Circulating Cell-Free Epigenomes
Razane El Hajj Chehade
Abstract 49
Preclinical efficacy of combined CDK4/6 & mTORC1 inhibition in translocation renal cell carcinoma
Shikha Gupta
Abstract 52
Spatial Transcriptomic Mapping Reveals Immune-inflamed Niches in Sarcomatoid Chromophobe Renal Cell Carcinoma (ChRCC)
Yan Tang
Abstract 53
Microenvironmental characteristics of disease relapse after nephrectomy in clear cell renal cell carcinoma
Yu Fujiwara
Abstract 54
Multimodal targeting of metastatic renal cell carcinoma via CD70-directed allogeneic CAR-NKT cells
Yan-Ruide Li
Abstract 55
The Prognostic Role of Circulating Tuor DNA (ctDNA) Clearance as a Biomarker in Localized and Metastatic Renal Cell Carcinoma (RCC): A Single Center Experience
Adanma Ayanambakkam
Abstract 56
NPRL2 loss silences STING signaling from genomic instability and confers immunotherapy resistance
Xiande Liu
Abstract 57
VHL and TP53 mutation status are not associated with response or progression-free survival in metastatic renal cell carcinoma treated with VEGF-targeted therapies
Daniela V. Castro
Abstract 58
Dissecting the Interplay between Bap1 and Pbrm1 in Renal Cell Carcinoma
Bingqing Xie
Abstract 59
Real-World Efficacy and Safety of Belzutifan in Sporadic Metastatic Renal Cell Carcinoma: A Multicenter Study from The City of Hope Enterprise
Charles B. Nguyen
Abstract 60
Systemically Administered Oncolytic Vaccinia Virus Enhances the In Vivo Antitumor Effects of RTKI and ANTI-PD-1 Based Therapies in an Immunocompetent Renal Cancer Model
N. Tran
Abstract 61
Predicting Immunotherapy Response in ccRCC using Deep Learning on Histopathological Slides
S. Rajaram
Abstract 62
The SLC1A1/EAAT3 Dicarboxylic Amino Acid Transporter is an Epigenetically Dysregulated Nutrient Carrier that Sustains Oncogenic Metabolic Programs
Treg Grubb
Abstract 63
Plasma Proteomic Profiling Reveals Distinct Mitochondrial Signatures in Chromophobe Renal Cell Carcinoma
Clara Steiner
Abstract 65
Treatment Patterns and Attrition Rates in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma in the US
Zeynep Irem Ozay
Abstract 66
Patient Perceptions of Biomarker Testing in Kidney Cancer from the International Kidney Cancer Coalition Global Patient Survey
Eric Jonasch
Abstract 68
Targeting the BBOX1-TBK1-mTORC1 Axis in Clear Cell Renal Cell Carcinoma
Chengheng Liao Ph.D.
Abstract 69
PAPMET2: A Phase II Randomized Trial of Cabozantinib with or without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma (PRCC): SWOG S2200
Benjamin L. Maughan
Abstract 70
FIT-001 (NCT06026410): A phase 1 clinical trial of the farnesyltransferase inhibitor KO-2806 in combination with cabozantinib in renal cell carcinoma
Adanma Ayanambakkam
Abstract 71
Video-educational intervention for Latinx patients with genitourinary malignancies
Regina Barragan-Carrillo
Abstract 72
Combination, Single Session Transarterial Embolization and Lipiodol Staining with Percutaneous Microwave Ablation for Central Renal Cell Carcinoma: A Pilot Study
Ahmed Farhan, M.D., MS
Abstract 73
Multiplexed Spatial Proteomic Profiling of a Real-World Cohort of Renal Cell Carcinoma Patients Treated with first-line Ipilimumab and Nivolumab
Noam S. Gaiger
Abstract 74
Spatial clustering of CD163 and FOXP3 cells in clear cell renal cell carcinoma lung metastases
Mitchell T. Hayes
Abstract 75
Statin-derived small-molecule inhibitors of metastasis (SIM) for advanced clear cell renal cell carcinoma
Junhui Hu
Abstract 76
Clinical and Molecular Characterization of KRAS mutations in Renal Cell Carcinoma
Andrea Lopez Sanmiguel
Abstract 77
Urine C-reactive protein content provides non-invasive molecular grading of renal cell carcinomas.
Jeremiah J Morrissey
Abstract 78
Investigating ECM alternative splicing in ccRCC kidney cancers
Timothy Shaw
Abstract 79
Immunosuppressive myeloid gene expression among patients with localized clear cell renal cell carcinoma
Linnea T Olsson
Abstract 80
Obesity Paradox in Localized Renal Cell Carcinoma: The Impact of BMI and Comorbidities on Survival Outcomes
Monica Sarker
Abstract 81
Real-World Characteristics and Treatment Patterns in Belzutifan-Treated Patients With Von Hippel–Lindau Disease
Vivek K. Narayan
Abstract 82
Transcriptomic Profiling Reveals Elevated Epithelial – Mesenchymal Transition and Inflammatory Pathway Effectors in Metastatic Chromophobe Renal Cell Carcinoma
Wafaa Bzeih
Abstract 83
Hemoglobin levels and clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) receiving hypoxia-inducible factor-2α inhibitor (HIF2i) monotherapy
Wassim Daoud Khatoun
Abstract 84
Diagnostic and Prognostic Value of Preoperative Plasma KIM-1 in Renal Cell Carcinoma: Insights from an Asian Population
Chia-Yen Lin
Abstract 85
Treatment Patterns in Metastatic Renal Cell Carcinoma Patients with DNA Damage Repair (DDR) Mutations
Nonna Shakhnazaryan
Abstract 86
G6PD and NADK in renal cell carcinoma subtypes: expression profiles and associations with pathological characteristics
Regia Lira Fusco
Abstract 87
Role of Ferroptosis Resistance in the Progression of Chromophobe Renal Cell Carcinoma
Joelle Chami
Abstract 88
Predictors and Survival Outcomes of Early Mortality in Metastatic Renal Cell Carcinoma in the Immunotherapy Era: A Population-based Retrospective Cohort Study
Aneeta Channar,MD
Abstract 89
Exploring the role of plasma Kidney Injury Molecule-1 (KIM-1) in Patients with Wilms’ Tumor
Liliana Ascione
Abstract 90
A Novel Murine Transgenic Model of SFPQ-TFE3-driven Renal Tumorigenesis: Mechanisms and Biomarkers
Kaushal Asrani
Abstract 91
The Staging of High-risk And Non-Metastatic Renal Cell Carcinoma with Preoperative imaging (SHARP) Model Identifies pT3 Tumors for Neoadjuvant Studies
Paz Lotan
Abstract 92
Engineering Immunocompetent Preclinical Models to Unmask Therapeutic Vulnerabilities in FH-Deficient RCC
Amrita M. Nargund
Abstract 93
Clinical characteristics, determinants and subsequent therapy of primary refractory metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study
Marc Eid
Abstract 94
Metabolic basis of redox balance in clear cell RCC
Anirban Kundu
Abstract 95
Characterization of Urine-Derived Cell Cultures from Healthy Volunteers and Patients with Clear Cell Renal Cell Carcinoma
Zahra Moghimi
Abstract 96
Integrating mutation, copy number alteration, and DNA methylation in assessing the survival and tumor micro-environment in clear cell Renal Cell Carcinoma
Erick Mboya
Abstract 97
Molecular and Therapeutic Advances: Triptolide and Minnelide Effects in Renal Cell Carcinoma Patient-Derived Xenografts
V. Chavez
ABSTRACT BOOK
Kidney Cancer Research Summit
July 17–18, 2025 – Boston, MA
Click the image above to download the Abstract Book.
Updated 07.14.25